A detailed history of Dcm Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Dcm Advisors, LLC holds 27,795 shares of ABBV stock, worth $5.67 Million. This represents 2.53% of its overall portfolio holdings.

Number of Shares
27,795
Previous 32,281 13.9%
Holding current value
$5.67 Million
Previous $5.88 Million 18.9%
% of portfolio
2.53%
Previous 2.47%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $694,387 - $810,889
-4,486 Reduced 13.9%
27,795 $4.77 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $1.25 Million - $1.42 Million
-7,804 Reduced 19.47%
32,281 $5.88 Million
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $749,507 - $844,121
5,447 Added 15.73%
40,085 $6.21 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $126,776 - $146,762
-949 Reduced 2.67%
34,638 $5.16 Million
Q2 2023

Sep 12, 2023

BUY
$132.51 - $164.9 $64,664 - $80,471
488 Added 1.39%
35,587 $4.79 Million
Q1 2023

Sep 12, 2023

SELL
$144.61 - $166.54 $38,032 - $43,800
-263 Reduced 0.74%
35,099 $5.59 Million
Q4 2022

Sep 08, 2023

BUY
$138.31 - $165.87 $1.9 Million - $2.28 Million
13,725 Added 63.43%
35,362 $5.72 Million
Q3 2022

Sep 08, 2023

SELL
$134.21 - $153.93 $50,597 - $58,031
-377 Reduced 1.71%
21,637 $2.9 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $143,124 - $181,958
1,040 Added 4.96%
22,014 $3.37 Million
Q1 2022

May 09, 2022

SELL
$131.98 - $163.75 $29,035 - $36,025
-220 Reduced 1.04%
20,974 $3.4 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $1.06 Million - $1.35 Million
9,910 Added 87.82%
21,194 $2.87 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $1.2 Million - $1.36 Million
11,284 New
11,284 $1.22 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $360B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Dcm Advisors, LLC Portfolio

Follow Dcm Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcm Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcm Advisors, LLC with notifications on news.